The first batch of drugs that are encouraged to be imitated have 34 varieties!

[industry trends of pharmaceutical Station] on June 20, the national health and Health Commission issued the announcement on the list of recommendations for the catalogue of drugs to be approved and encouraged to imitate (hereinafter referred to as the announcement)   According to the formula, in order to implement the opinions on reforming and improving the supply guarantee and use policy of generic drugs and the notice on printing and distributing the work plan for accelerating the implementation of supply guarantee and use policy of generic drugs issued by 12 departments such as the National Health Commission, the National Health Commission, together with the Ministry of science and technology and other departments, organized experts to go through Through selection and demonstration, the list of recommendations for the catalogue of drugs to be approved and imitated is put forward It is hereby publicized for 5 working days According to the list of drugs to be imitated, there are 34 drugs without registration application and insufficient competition, including abacavir and lipirin, children's drug niticinon and thiazolidine Therefore, for pharmaceutical companies, those involved in these 34 drugs who plan ahead of time or have greater market opportunities In fact, in order to encourage the development of generic drugs, as early as April 2018, China issued the opinions on reforming and improving the supply guarantee and use policy of generic drugs, which clearly defined the scope of drugs to encourage generic drugs: "clinically necessary, effective and short supply" At the same time, it was mentioned that we should promote the research and development of generic drugs, regularly formulate and publish the catalogue of drugs to encourage generic drugs, and guide the research and development, registration and production of enterprises In addition, it is encouraged to imitate the drugs needed for the prevention and treatment of major infectious diseases and rare diseases, for the disposal of public health emergencies, for children to use drugs and other drugs The Opinions also mentioned that we should improve the support policies and promote the high-quality generic drugs to enter clinical use as soon as possible from six aspects At the end of 2018, 12 departments including the National Health Commission issued the notice on printing and distributing the work plan for accelerating the implementation of the supply guarantee and use policy of generic drugs, which also requires promoting the alternative use of generic drugs At the same time, the change requires deepening the reform of medical insurance payment mode Through the guidance measures of medical insurance drug payment standard, the generic drugs and the original research drugs that pass the consistency evaluation of quality and efficacy will be paid according to the same standard step by step At the beginning of this year, according to the requirements of the work plan on accelerating the implementation of the supply guarantee and use policy of generic drugs, a batch of drug catalogues encouraging generic drugs will be issued before the end of June 2019, which will guide the research, development, registration and production of enterprises At the same time, priority will be given to the review and approval of generic drugs included in the catalogue Now, with the formal publication of the first list of recommendations to encourage generic drug catalog, it also means that the development of generic drug industry will be substantially improved, which is conducive to the birth of more high-quality generic drug R & D and production In a deeper sense, encouraging generic drugs to replace the original drugs is actually reducing the burden of health insurance Industry data shows that the income of urban basic medical insurance fund increased from 553.9 billion yuan to 1793.2 billion yuan from 2011 to 2017, with an average annual growth rate of 21.63%; the expenditure of medical insurance fund increased from 443.1 billion yuan to 1442.2 billion yuan from 2011 to 2016, with an average annual growth rate of 21.73% It can be seen that the overall growth rate of income of China's health insurance fund is lower than that of expenditure every year, and the risk of health insurance fund underperforming may appear in the future The industry estimates that if the current situation of substituting the original drugs through the generic drug consistency evaluation varieties can be realized, it can save tens of billions of yuan of medical insurance costs for the country every year.